Background: the purpose of this study was to retrospectively assess the technical and clinical outcomes, overall survival and prognostic factors for prolonged survival after yttrium-90 radioembolization as a salvage therapy for patients with chemorefractory liver-only or liverdominant colorectal metastases.
INTRODUCTION
Colorectal cancer is the second most common cancer in Europe and 15 -25% of patients develop liver metastases. If these patients are ineligible for local ablative therapies like radiofrequency ablation (RFA) or for surgical resection, chemotherapeutic treatment remains the therapeutic mainstay for this patient population with overall survival beyond 2 years [1] [2] . radioembolization results in improved survival compared to treatment with 5-FU alone [3] in chemorefractory patients with liver-only or liver-dominant mCRC. Based on these findings, radioembolization is recommended in the guidelines from the European Society of Medical Oncology (ESMO) for patients with liver-limited metastases in whom the available chemotherapeutic options have failed [2] .
Several observational cohort studies [4] [5] [6] [7] [8] [9] [10] as well as a few meta-analyses dealing with radioembolization for chemorefractory mCRC have been published, all of them demonstrating the relative safety of the radioembolization technique and the potential for better survival. However, only limited data on late toxicity of 90 Y in this patient population are available [11] [12] [13] . Additionally, little information is available about potential prognostic factors for prolonged survival. Postprocedural radiological response seems to be the best prognostic parameter for better survival. However, no data are available on the potential for use of preprocedural (laboratory and radiological) parameters for survival prognosis.
In this manuscript, we report the early and late side-effects of radioembolization in a 'real world' patient population with chemorefractory mCRC at a tertiary referral centre for digestive cancers over a 9 year time span. Furthermore, we report overall survival and have
analysed the prognostic potential of preprocedural factors for prediction of improved survival.
MATERIALS AND METHODS

Patient demographics
From January 2005 until January 2014, 88 patients with chemorefractory colorectal liver metastases were selected for 90 Y radioembolization by the institutional tumor board for digestive cancers at University Hospitals Leuven, including medical, surgical and radiation oncologists, pathologists, interventional and diagnostic radiologists and nuclear medicine physicians.
All patients presented with colorectal liver metastases refractory to several lines of chemotherapy, including oxaliplatin and irinotecan-based schemes, with no indication for surgical resection or local ablative treatments. Tumor load within the liver as well as extrahepatic metastatic spread were assessed by body computed tomography (CT) and/or 18 Ffluorodeoxyglucose positron emission tomography (PET) with or without CT. After sheath removal and femoral compression for 10 minutes, the patient is immediately referred to the nuclear medicine department for planar scintigraphy within one hour after anti-emetics and morphine derivatives were given when required. Steroids, proton pump inhibitors or antibiotics were not systematically administered.
All bilobar SIRT procedures were performed in one session.
Y microsphere activity calculation
Activity calculation was mainly performed using the body surface area (BSA) method. In patients with diffuse bilobar disease the activity injected was the one calculated using the BSA method. Initially these values were reduced if the LSF was >10% (10-15%: reduction to 80%; >15%-20%: 60%) but in patients treated later the activity was only reduced if the calculated dose would result in a lung dose of more than 30 Gy, with a reduction leading to a 30 Gy lung dose. In patients with unilobar disease in which activity escalation could be performed the partition model was used.
Y brehmsstrahlung imaging
Patients were imaged on the day of the 90 Y microsphere infusion or the next day.
Brehmsstrahlung imaging was performed on the same gamma cameras as used for the (AUC) or C-index for binary responses, indicating the probability that the predictions for a random pair of subjects are concordant with their outcomes [17] .
All tests are two-sided and a 5% significance level is assumed for all tests. All analyses have been performed using SAS software, version 9.3 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA).
RESULTS
Initially, 88 patients were selected for angiographic workup; however 17 out of these 88 patients (19%) were excluded from further SIRT therapy based on an LSF of > 20% (n=7); leakage of 99m Tc-MAA to the gastroduodenal area, not correctable by repeat angiography and coil embolization (n=1), prior external beam radiotherapy to the liver unknown at the time of angiographic workup and progression of disease resulting in excessive extrahepatic disease during the time period between angiographic workup and the SIRT procedure (n=8). Overall, 71 patients underwent both angiographic workup and transcatheter SIRT therapy and these patients are studied below.
Demographic data
The patients' demographics are summarized in Table I. The majority of included patients were men, presenting with synchronous, bilobar colorectal liver metastases with no extrahepatic tumor load.
Laboratory data, including platelet count, carcinoembryonic antigen (CEA), bilirubin, kidney and liver function tests are summarized in Table II .
All patients (n=71 ; 100%) had progressed on second line chemotherapy ; 44 out of 71 patients (62%) had progressed on third line chemotherapy. In total 40 out of 71 patients (56%) received cetuximab prior to 90 Y radioembolization.
At the time inclusion for SIRT-therapy, 2 out of 71 included patients (3%) had a bilirubine level > 2.5 mg/ml and 20 out of 71 patients (28%) had a bilirubine level > 1 mg/dl.
Radiological and nuclear medicine data
During angiographic workup, the gastroduodenal artery was coiled in 60 patients (85%), the right gastric artery in 30 patients (42%), the left gastric artery in 3 patients (4%), a pancreatic artery in 2 patients (3%), the supraduodenal artery in 1 patient (1%) and the phrenic artery in 1 patient (1%). Finally, flow redistribution was obtained after coil embolization of the left hepatic artery in 4 patients (6%) and of the accessory branch to segment 4 in 2 patients (3%).
The LSF based on the 99m Tc-MAA scintigraphy had a mean value of 8% with a standard deviation of 3.5%, a median value of 7.8% with an IQR between 5.9% and 9.8% and a range between 3% and 19% (Fig. 1) . The mean time interval between the workup angiographic procedure and the 90 Y infusion therapy was 25 days (standard deviation: 13 days).
The total liver volume, liver tumor volume, diameter of the largest liver metastasis, the number of patients treated with a reduced activity and the total activity of 90 Y microspheres administered to the patients are summarized in Table III . 2a-b, Fig. 3a-b) . The upper gastrointestinal, variceal bleeding was managed using endoscopic techniques; the refractory ascites by repeated parascenteses.
Disease free survival, time to tumor progression in the liver and overall survival.
Radiological follow-up data for the assessment of disease free survival and time to tumor progression in the liver was available in 61 out of 71 patients (86%), demonstrating a median disease free survival of 3 months (mean 4.6 months, standard deviation 4.1 months) and a median time to progression in the liver of 4 months (mean 6.0 months, standard deviation 5.1 months). One patient (1.5%) could be downstaged for combined surgical segmentectomy in the right liver lobe and radiofrequency ablation in the left liver lobe. Overall, estimated survival at 6 and 12 months is 65% and 30% respectively with a 50% estimated mortality after 8.0 months (Table IV and Fig. 4 ).
Factors potentially influencing survival
Univariate analysis, summarized in Table V , demonstrates an increased risk of early mortality for increased baseline alkaline phosphatase values; a non-linear correlation was found between bilirubin levels and total tumor volume and prolonged survival: patients with the lowest baseline values for bilirubin and total tumor volume had a lower risk of early mortality, whereas intermediate values had the highest risk of early death (Fig. 5, Fig. 6 ).
Increased AST levels are associated with a higher risk of early mortality, but the correlation is non-linear with a flattening of the effect for the lowest and highest levels (Fig. 7) .
Finally, multivariate analysis demonstrates a linear increase in early mortality after SIRT in patients with higher baseline alkaline phosphatase levels: for each increase by 10 units, the risk of death rises by 1% (Fig. 8) . The CPE value of this model is 0.65, meaning that in 65%
of patient pairs the model will give a correct prognosis for which of the two patients the best survival can be predicted (Table VI) .
DISCUSSION
This report confirms the low complication rate related to the infusion of 90 Y microspheres into the liver, in line with other studies dealing with SIRT for treatment of colorectal liver metastases: prolonged abdominal pain, fatigue and radiation-induced gastroduodenal ulcers were identified in respectively 46%, 55% and 7%, which is within the range of other published experiences [12] . We also identified 3 patients (4%) presenting with a significant increase in bilirubin levels within 30 days after the 90 Y infusion. This phenomenon may be related to radioembolization-induced liver disease, although rapid progression of liver disease may potentially also result in elevated bilirubin levels. Three patients (4%) presented with cirrhosis-like changes in the liver parenchyma, associated with severe symptoms of portal hypertension, including refractory ascites (n=2) and variceal upper gastrointestinal bleeding (n=1), respectively 19, 12 and 12 months after 90 Y treatment. This complication, which we defined as radioembolization-induced portal hypertension, is most probably an extreme clinical presentation of the radiation-induced liver fibrosis described by Jacobs et al. [11] .
Potentially, this late complication might be avoided if these patients had received corticosteroids as suggested by Sangro et al [18] . As these symptoms of radioembolizationinduced portal hypertension were identified at one year or later after SIRT-therapy, the potential incidence of this side effect might be much higher than 4% if patients with a potential better survival prognosis will be treated with SIRT, like patients treated with SIRT in an earlier stage of their disease.
The general overall survival after 90 Y radioembolization in our cohort of chemorefractory colorectal cancer patients shows a median overall survival of 8.0 months and 30% of the treated patients were still alive after 1 year of follow-up. In a systematic review, Saxena et al. [19] found an overall survival for patients with colorectal liver metastases who were treated with 90 Y microspheres ranging from 8.0 months to 36 months. The lowest survival results were found in the patient populations previously treated with the most lines of intravenous chemotherapy, as in our patient population [20] . Additionally, we did not administer an intravenous 5-FU infusion immediately after the 90 Y infusion as described by Hendlisz et al.
[3], which might also have a beneficial effect on the survival outcome. The median overall survival of 8.0 months after 90 Y -radioembolization for colorectal liver metastases in patients refractory to all types of chemotherapy seems to be somewhat better than the overall survival after best supportive care (5.0 months) or after regorafenib (6.4 months) (26) . However, a prospective, randomized trial comparing 90 Y to Regorafenib might give the answer to better determine the place of these treatments in patients with colorectal metastases, refractory to all types of currently available chemotherapies.
The median time to tumor progression in the liver was 4.4 months, which is in line with other studies dealing with the same patient population [2] . In this cohort of patients with chemorefractory colorectal liver metastases, downstaging to surgical resection remains rare: only 1 patient was finally able to be resected and these data confirm those obtained by
Cosimelli et al. [5] .
We also found a substantial number of patients (n=19) who were excluded from 90 Y microsphere infusion after the workup procedure. Exclusion from 90 Y microsphere infusion was mainly related to a high liver-lung shunt of > 20% ( n=7) or to rapid disease progression during the interval between angiographic workup and 90 Y radioembolization (n=8). The mean time interval seems to be relatively long (25 days) and the number of excluded patients could possibly be reduced if a shorter time interval could be considered.
We also analysed several pre-interventional biochemical and imaging parameters which potentially influence the overall survival. In a univariable analysis, higher alkaline phosphatase, AST and ALT values were associated with a higher risk of early mortality; for bilirubin and total tumor volume values, better survival seems to be observed for the lowest values while intermediate values were associated with an increased risk of early mortality. A flattening or even a discrete decrease in early deaths was noted for the highest pre-treatment levels of bilirubin and total tumor load. Based on these results, patients with both borderline high bilirubin and borderline high tumor volume levels should not be excluded from 90 Y radioembolization, which is in line with the results of Jacobs et al. [6] . However, other studies suggest a higher risk of early mortality in patients with a higher tumor burden [21] [22] [23] [24] .
The presented study cannot confirm the results of Deipolyi et al. [25] showing an increased risk of early widespread metastatic growth and subsequently early mortality in those patients with a high liver-lung shunt (p=0.1087). Deipolyi et al [25] hypothesize that a higher liverlung shunt is associated with larger vascular, intratumoral shunts between the hepatic artery and hepatic vein, thereby facilitating malignant cell migration from the liver to the lungs and other organs.
In a multivariate analysis, a higher alkaline phosphatase level and an intermediate bilirubin level are associated with a higher risk of early mortality.
In conclusion, this study confirms the good safety profile of 90 Y microspheres administered in the hepatic artery for the treatment of colorectal liver metastases with an overall survival of 8 months in chemorefractory mCRC patients with liver-limited or liver-predominant metastases. However, a relatively high number of patients were excluded from further treatment after the workup mainly due to a high liver-lung shunt or rapid disease progression during the time period between the workup and 90 Y microsphere administration.
Pre-interventional higher bilirubin, alkaline phosphatase and AST levels as well as a higher pretreatment tumor burden are associated with higher risk of early mortality. demonstrates a higher early mortality in patients with a higher preprocedural alkaline phosphatase level.
